Cheaper or pricier? trial pits two eye drugs against each other for diabetes vision loss
NCT ID NCT06850571
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares two drugs, aflibercept and bevacizumab, given as eye injections to treat diabetic maculopathy, a complication of diabetes that can blur vision. About 102 Iraqi patients with type 2 diabetes will receive monthly injections for three months. Researchers will measure vision changes, eye thickness, side effects, and cost to see which drug offers better value.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aflibercept and bevacizumab (anti-VEGF drugs injected into the eye)
- What this could lead to
- If successful, this could show which drug works better and is more cost-effective for treating diabetic maculopathy, helping guide treatment choices.
- What could go wrong
- This is a small, single-country trial with only 102 participants, so results may not apply broadly. Both drugs have known risks like eye infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 102 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with type 2 diabetes mellites. * Patients diagnosed with diabetic maculopathies, including focal and diffuse maculopathies, according to Early Treatment of Diabetic Retinopathy Study (ETDRS) criteria * Patients with reduced or reduced vision (6/9-6/90) according to visual acuity and significant foveolar thickening on OCT (more than 250 μm) * Patients will be treated with intravitreal anti-VEGF treatment, aflibercept, or bevacizumab for three successive monthly injections. Exclusion Criteria: * Patients with type 1 diabetes mellites * Patients with type 2 on insulin therapy. * Patients who were previously treated with intravitreal anti-VEGF within the previous three months or intravitreal corticosteroids for six months * Prior macular photocoagulation or photodynamic therapy, prior intraocular surgeries within three months (laser \& surgery may cause edema) * Pregnant or nursing women * In patients with a history of thromboembolic events, systemic VEGF inhibition is likely to cause cardiovascular complications, such as arterial thromboembolic events. * Patients major surgery within the previous one year or planned within the next few months that may interfere with anti-VEGF treatment * Uncontrolled hypertension as hypertension is associated with the use of VEGF antagonists. * Known coagulation abnormalities or current use of anticoagulative medication other than aspirin. * Hemorrhagic macular infarction is reported with the use of VEGF antagonists. * Patients with intraocular pressure more than 25 mmHg * Presence of iris neovascularization/vitreous hemorrhage
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic maculopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baghdad Medical City Complex
RECRUITINGBaghdad, 10001, Iraq
More trials for these conditions
Other studies related to the condition(s) this trial covers.